{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T10:07:49Z","timestamp":1789034869655,"version":"build-2803163510"},"reference-count":47,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Extant literature indicates mitochondrial dysfunction may contribute to the pathophysiology of depressive disorders. Preclinical data indicate that anesthetic doses of ketamine are associated with deficits in mitochondrial viability and function. Ketamine and esketamine have demonstrated rapid antidepressant effects in persons with difficult-to-treat depressive disorders. Herein, we aim to synthesize literature reporting on the effect of antidepressant doses of ketamine and esketamine in vivo versus in vitro on mitochondrial viability and function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We performed a systematic review of previous studies on PubMed, Ovid, and Scopus databases from inception to November 30, 2025. Preclinical studies reporting on the effect of antidepressant doses of ketamine and\/or esketamine in mitochondrial viability, structure\/morphology, bioenergetics, and metabolic function were sought for inclusion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Thirteen studies were included. Lower ketamine\/esketamine concentrations generally did not adversely affect membrane potential, oxidative phosphorylation, respiration, or bioenergetics, whereas higher concentrations or prolonged exposure induced mitochondrial dysfunction in some models. Additional evaluation of the safety of ketamine\/esketamine on mitochondria in humans is required.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Preliminary research suggests that ketamine at lower concentrations may not adversely affect brain mitochondrial viability or bioenergetic function, but requires further validation. The reported effects on mitochondrial viability and function are preclinical, model- and dose-dependent and derived from limited heterogeneous literature. This study generates the hypothesis that ketamine\u2019s antidepressant mechanism of action may be partially mediated by insulin-sensitive metabolic pathways, energetically supporting synaptic remodeling and neurogenesis. Incorporation of mitochondrial and metabolic biomarkers into ketamine clinical trials is a current research imperative.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/02698811261481085","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:45:27Z","timestamp":1788781527000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["The effect of ketamine on mitochondrial bioenergetics, viability, and function: A systematic review"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-0928-3433","authenticated-orcid":false,"given":"Sabrina","family":"Wong","sequence":"first","affiliation":[{"name":"Brain and Cognition Discovery Foundation, Toronto, ON, Canada"},{"name":"Poul Hansen Family Centre for Depression, University Health Network, Toronto, ON, Canada"},{"name":"Department of Pharmacology &amp; Toxicology, University of Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gia Han","family":"Le","sequence":"additional","affiliation":[{"name":"Brain and Cognition Discovery Foundation, Toronto, ON, Canada"},{"name":"Poul Hansen Family Centre for Depression, University Health Network, Toronto, ON, Canada"},{"name":"Institute of Medical Science, University of Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simryn","family":"Selby","sequence":"additional","affiliation":[{"name":"Poul Hansen Family Centre for Depression, University Health Network, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0828-0647","authenticated-orcid":false,"given":"Stavroula","family":"Bargiota","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Thessaly, Larissa, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana K.","family":"Orsini","sequence":"additional","affiliation":[{"name":"Poul Hansen Family Centre for Depression, University Health Network, Toronto, ON, Canada"},{"name":"Department of Pharmacology &amp; Toxicology, University of Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Di Luch","sequence":"additional","affiliation":[{"name":"Poul Hansen Family Centre for Depression, University Health Network, Toronto, ON, Canada"},{"name":"Department of Pharmacology &amp; Toxicology, University of Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7089-9944","authenticated-orcid":false,"given":"Shreya","family":"Vasudeva","sequence":"additional","affiliation":[{"name":"Poul Hansen Family Centre for Depression, University Health Network, Toronto, ON, Canada"},{"name":"Institute of Medical Science, University of Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8403-5206","authenticated-orcid":false,"given":"Gabrielle","family":"Lovell","sequence":"additional","affiliation":[{"name":"Poul Hansen Family Centre for Depression, University Health Network, Toronto, ON, Canada"},{"name":"Department of Pharmacology &amp; Toxicology, University of Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4773-2191","authenticated-orcid":false,"given":"Joshua D.","family":"Rosenblat","sequence":"additional","affiliation":[{"name":"Poul Hansen Family Centre for Depression, University Health Network, Toronto, ON, Canada"},{"name":"Department of Pharmacology &amp; Toxicology, University of Toronto, ON, Canada"},{"name":"Institute of Medical Science, University of Toronto, ON, Canada"},{"name":"Department of Psychiatry, University of Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4733-2523","authenticated-orcid":false,"given":"Roger S.","family":"McIntyre","sequence":"additional","affiliation":[{"name":"Department of Pharmacology &amp; Toxicology, University of Toronto, ON, Canada"},{"name":"Department of Psychiatry, University of Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"crossref","unstructured":"Ahtiainen A Annala I Rosenholm M et al. (2023) Ketamine reduces electrophysiological network activity in cortical neuron cultures already at sub-micromolar concentrations: Impact on TrkB-ERK1\/2 signaling. Neuropharmacology 229: 109481. https:\/\/doi.org\/10.1016\/j.neuropharm.2023.109481","DOI":"10.1016\/j.neuropharm.2023.109481"},{"key":"e_1_3_2_3_1","doi-asserted-by":"crossref","unstructured":"Bahji A Zarate CA Vazquez GH (2021) Ketamine for bipolar depression: A systematic review. International Journal of Neuropsychopharmacology 24: 535\u2013541. https:\/\/doi.org\/10.1093\/ijnp\/pyab023","DOI":"10.1093\/ijnp\/pyab023"},{"key":"e_1_3_2_4_1","doi-asserted-by":"crossref","unstructured":"Bai X Yan Y Canfield S et al. (2013) Ketamine enhances human neural stem cell proliferation and induces neuronal apoptosis via reactive oxygen species\u2013mediated mitochondrial pathway. Anesthesia & Analgesia 116: 869\u2013880. https:\/\/doi.org\/10.1213\/ANE.0b013e3182860fc9","DOI":"10.1213\/ANE.0b013e3182860fc9"},{"key":"e_1_3_2_5_1","doi-asserted-by":"crossref","unstructured":"Beaglehole B Glue P Neehoff S et al. (2025) Six weeks open-label oral ketamine for patients with treatment-resistant depression post-traumatic stress disorder or obsessive-compulsive disorder. Journal of Psychopharmacology 39: 571\u2013576. https:\/\/doi.org\/10.1177\/02698811251344710","DOI":"10.1177\/02698811251344710"},{"key":"e_1_3_2_6_1","doi-asserted-by":"crossref","unstructured":"Bennett R Yavorsky C Bravo G. (2022) Ketamine for bipolar depression: Biochemical psychotherapeutic and psychedelic approaches. Frontiers in Psychiatry 13: 867484. https:\/\/doi.org\/10.3389\/fpsyt.2022.867484","DOI":"10.3389\/fpsyt.2022.867484"},{"key":"e_1_3_2_7_1","doi-asserted-by":"crossref","unstructured":"Bloomfield A Chan N Fryml L et al. (2023) Ketamine for chronic pain and mental health: Regulations legalities and the growth of infusion clinics. Current Pain and Headache Reports 27: 579\u2013585. https:\/\/doi.org\/10.1007\/s11916-023-01150-1","DOI":"10.1007\/s11916-023-01150-1"},{"key":"e_1_3_2_8_1","doi-asserted-by":"crossref","unstructured":"Braun S Gaza N Werdehausen R et al. (2010) Ketamine induces apoptosis via the mitochondrial pathway in human lymphocytes and neuronal cells. British Journal of Anaesthesia 105: 347\u2013354. https:\/\/doi.org\/10.1093\/bja\/aeq169","DOI":"10.1093\/bja\/aeq169"},{"key":"e_1_3_2_9_1","doi-asserted-by":"crossref","unstructured":"Calder CN Kwan ATH Teopiz KM et al. (2024) Number needed to treat (NNT) for ketamine and esketamine in adults with treatment-resistant depression: A systematic review and meta-analysis. Journal of Affective Disorders 356: 753\u2013762. https:\/\/doi.org\/10.1016\/j.jad.2024.04.039","DOI":"10.1016\/j.jad.2024.04.039"},{"key":"e_1_3_2_10_1","doi-asserted-by":"crossref","unstructured":"Choudhury D Autry AE Tolias KF et al. (2021) Ketamine: Neuroprotective or neurotoxic? Frontiers in Neuroscience 15: 672526. https:\/\/doi.org\/10.3389\/fnins.2021.672526","DOI":"10.3389\/fnins.2021.672526"},{"key":"e_1_3_2_11_1","unstructured":"Covidence (2026) Better systematic review management [WWW Document]. Available at: https:\/\/www.covidence.org\/ (accessed 19 June 2025)."},{"key":"e_1_3_2_12_1","doi-asserted-by":"crossref","unstructured":"Culmsee C Michels S Scheu S et al. (2018) Mitochondria Microglia and the immune system-how are they linked in affective disorders? Frontiers in Psychiatry 9: 739. https:\/\/doi.org\/10.3389\/fpsyt.2018.00739","DOI":"10.3389\/fpsyt.2018.00739"},{"key":"e_1_3_2_13_1","doi-asserted-by":"crossref","unstructured":"De la Rosa Gonz\u00e1lez A Guerra-Ojeda S Camacho-Villa MA et al. (2024) Effect of probiotics on gastrointestinal health through the aryl hydrocarbon receptor pathway: A systematic review. Foods 13: 3479. https:\/\/doi.org\/10.3390\/foods13213479","DOI":"10.3390\/foods13213479"},{"key":"e_1_3_2_14_1","doi-asserted-by":"crossref","unstructured":"Deng C-Y Yu X-Y Kuang S-J et al. (2008) Electrophysiological effects of ketamine on human atrial myocytes at therapeutically relevant concentrations. Clinical and Experimental Pharmacology and Physiology 35: 1465\u20131470. https:\/\/doi.org\/10.1111\/j.1440-1681.2008.05012.x","DOI":"10.1111\/j.1440-1681.2008.05012.x"},{"key":"e_1_3_2_15_1","doi-asserted-by":"crossref","unstructured":"Duman RS Aghajanian GK Sanacora G et al. (2016) Synaptic plasticity and depression: New insights from stress and rapid-acting antidepressants. Nature Medicine 22: 238\u2013249. https:\/\/doi.org\/10.1038\/nm.4050","DOI":"10.1038\/nm.4050"},{"key":"e_1_3_2_16_1","doi-asserted-by":"crossref","unstructured":"Emmerzaal TL Jacobs L Geenen B et al. (2021) Chronic fluoxetine or ketamine treatment differentially affects brain energy homeostasis which is not exacerbated in mice with trait suboptimal mitochondrial function. European Journal of Neuroscience 53: 2986\u20133001. https:\/\/doi.org\/10.1111\/ejn.14901","DOI":"10.1111\/ejn.14901"},{"key":"e_1_3_2_17_1","doi-asserted-by":"crossref","unstructured":"Gerhard DM Pothula S Liu R-J. et al. (2020) GABA interneurons are the cellular trigger for ketamine\u2019s rapid antidepressant actions. Journal of Clinical Investigation 130: 1336\u20131349. https:\/\/doi.org\/10.1172\/JCI130808","DOI":"10.1172\/JCI130808"},{"key":"e_1_3_2_18_1","doi-asserted-by":"crossref","unstructured":"Guevara MA Garc\u00eda Men\u00e9ndez SM Barrutieta-Arberas I et al. (2025) Effect of acute administration of different ketamine doses on anxiety and metabolic activity of the amygdala in rats. Neuropsychobiology 1\u20138. https:\/\/doi.org\/10.1159\/000547982","DOI":"10.1159\/000547982"},{"key":"e_1_3_2_19_1","doi-asserted-by":"crossref","unstructured":"Heroiu I Le GH Sioufi M-C et al. (2026) Ketamine for the treatment of Obsessive-Compulsive Disorder (OCD): A systematic review on efficacy and tolerability. Clinical Neuropharmacology. Epub ahead of print 19 June 2026. https:\/\/doi.org\/10.1097\/WNF.0000000000000692","DOI":"10.1097\/WNF.0000000000000692"},{"key":"e_1_3_2_20_1","doi-asserted-by":"crossref","unstructured":"Himmelseher S Pfenninger E Kochs E et al. (2000) S(+)-ketamine up-regulates neuronal regeneration associated proteins following glutamate injury in cultured rat hippocampal neurons. Journal of Neurosurgical Anesthesiology 12: 84\u201394. https:\/\/doi.org\/10.1097\/00008506-200004000-00003","DOI":"10.1097\/00008506-200004000-00003"},{"key":"e_1_3_2_21_1","doi-asserted-by":"crossref","unstructured":"Hroudov\u00e1 J Fi\u0161ar Z (2012) In vitro inhibition of mitochondrial respiratory rate by antidepressants. Toxicology Letters 213: 345\u2013352. https:\/\/doi.org\/10.1016\/j.toxlet.2012.07.017","DOI":"10.1016\/j.toxlet.2012.07.017"},{"key":"e_1_3_2_22_1","doi-asserted-by":"crossref","unstructured":"Ito H Uchida T Makita K (2015) Ketamine causes mitochondrial dysfunction in human induced pluripotent stem cell-derived neurons. PLoS ONE 10: e0128445. https:\/\/doi.org\/10.1371\/journal.pone.0128445","DOI":"10.1371\/journal.pone.0128445"},{"key":"e_1_3_2_23_1","doi-asserted-by":"crossref","unstructured":"Krystal JH Kavalali ET Monteggia LM (2024) Ketamine and rapid antidepressant action: New treatments and novel synaptic signaling mechanisms. Neuropsychopharmacology 49: 41\u201350. https:\/\/doi.org\/10.1038\/s41386-023-01629-w","DOI":"10.1038\/s41386-023-01629-w"},{"key":"e_1_3_2_24_1","doi-asserted-by":"crossref","unstructured":"Li SW Kumpf KT Urrutia J et al. (2025) Ketamine for depression but at what cost? A review of Ketamine\u2019s neurotoxic effects from preclinical and human studies. American Journal of Psychiatry 182: 903\u2013912. https:\/\/doi.org\/10.1176\/appi.ajp.20250276","DOI":"10.1176\/appi.ajp.20250276"},{"key":"e_1_3_2_25_1","doi-asserted-by":"crossref","unstructured":"\u013dupt\u00e1k M Fi\u0161ar Z Hroudov\u00e1 J (2022) Agomelatine ketamine and vortioxetine attenuate energy cell metabolism: In vitro study. International Journal of Molecular Sciences 23: 13824. https:\/\/doi.org\/10.3390\/ijms232213824","DOI":"10.3390\/ijms232213824"},{"key":"e_1_3_2_26_1","doi-asserted-by":"crossref","unstructured":"McIntyre RS Rasgon N Goldberg J et al. (2025) The effect of glucagon-like peptide-1 and glucose dependent insulinotropic polypeptide receptor agonists on neurogenesis differentiation and plasticity (Neuro-GDP): Potential mechanistically informed therapeutics in the treatment and prevention of mental disorders. CNS Spectrums 30: e23. https:\/\/doi.org\/10.1017\/S1092852925000124","DOI":"10.1017\/S1092852925000124"},{"key":"e_1_3_2_27_1","doi-asserted-by":"crossref","unstructured":"McIntyre RS Rosenblat JD Nemeroff CB et al. (2021) Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: An international expert opinion on the available evidence and implementation. The American Journal of Psychiatry 178: 383\u2013399. https:\/\/doi.org\/10.1176\/appi.ajp.2020.20081251","DOI":"10.1176\/appi.ajp.2020.20081251"},{"key":"e_1_3_2_28_1","doi-asserted-by":"crossref","unstructured":"Moaddel R Farmer CA Yavi M. et al. (2023) Cerebrospinal fluid exploratory proteomics and ketamine metabolite pharmacokinetics in human volunteers after ketamine infusion. iScience 26: 108527. https:\/\/doi.org\/10.1016\/j.isci.2023.108527","DOI":"10.1016\/j.isci.2023.108527"},{"key":"e_1_3_2_29_1","doi-asserted-by":"crossref","unstructured":"Orhurhu V Orhurhu MS Bhatia A et al. (2019) Ketamine infusions for chronic pain: A systematic review and meta-analysis of randomized controlled trials. Anesthesia & Analgesia 129: 241\u2013254. https:\/\/doi.org\/10.1213\/ANE.0000000000004185","DOI":"10.1213\/ANE.0000000000004185"},{"key":"e_1_3_2_30_1","doi-asserted-by":"crossref","unstructured":"Page MJ McKenzie JE Bossuyt PM et al. (2021) The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 372: n71. https:\/\/doi.org\/10.1136\/bmj.n71","DOI":"10.1136\/bmj.n71"},{"key":"e_1_3_2_31_1","doi-asserted-by":"crossref","unstructured":"Peltoniemi MA Hagelberg NM Olkkola KT et al. (2016) Ketamine: A review of clinical pharmacokinetics and pharmacodynamics in anesthesia and pain therapy. Clinical Pharmacokinetics 55: 1059\u20131077. https:\/\/doi.org\/10.1007\/s40262-016-0383-6","DOI":"10.1007\/s40262-016-0383-6"},{"key":"e_1_3_2_32_1","doi-asserted-by":"crossref","unstructured":"Price RB Duman R (2020) Neuroplasticity in cognitive and psychological mechanisms of depression: An integrative model. Molecular Psychiatry 25: 530\u2013543. https:\/\/doi.org\/10.1038\/s41380-019-0615-x","DOI":"10.1038\/s41380-019-0615-x"},{"key":"e_1_3_2_33_1","doi-asserted-by":"crossref","unstructured":"Rezin GT Gon\u00e7alves CL Daufenbach JF et al. (2010) Effect of chronic administration of ketamine on the mitochondrial respiratory chain activity caused by chronic mild stress. Acta Neuropsychiatrica 22: 292\u2013299. https:\/\/doi.org\/10.1111\/j.1601-5215.2010.00500.x","DOI":"10.1111\/j.1601-5215.2010.00500.x"},{"key":"e_1_3_2_34_1","doi-asserted-by":"crossref","unstructured":"Rezin GT Gon\u00e7alves CL Daufenbach JF et al. (2009) Acute administration of ketamine reverses the inhibition of mitochondrial respiratory chain induced by chronic mild stress. Brain Research Bulletin 79: 418\u2013421. https:\/\/doi.org\/10.1016\/j.brainresbull.2009.03.010","DOI":"10.1016\/j.brainresbull.2009.03.010"},{"key":"e_1_3_2_35_1","doi-asserted-by":"crossref","unstructured":"Rigg N Abu-Hijleh FA Patel V et al. (2022) Ketamine-induced neurotoxicity is mediated through endoplasmic reticulum stress in vitro in STHdhQ7\/Q7 cells. NeuroToxicology 91: 321\u2013328. https:\/\/doi.org\/10.1016\/j.neuro.2022.06.004","DOI":"10.1016\/j.neuro.2022.06.004"},{"key":"e_1_3_2_36_1","doi-asserted-by":"crossref","unstructured":"Robinson BL Dumas M Ali SF et al. (2018) Mechanistic studies on ketamine-induced mitochondrial toxicity in zebrafish embryos. Neurotoxicology and Teratology 69: 63\u201372. https:\/\/doi.org\/10.1016\/j.ntt.2017.12.005","DOI":"10.1016\/j.ntt.2017.12.005"},{"key":"e_1_3_2_37_1","doi-asserted-by":"crossref","unstructured":"Slikker W Liu F Rainosek SW et al. (2015) Ketamine-induced toxicity in neurons differentiated from neural stem cells. Molecular Neurobiology 52: 959\u2013969. https:\/\/doi.org\/10.1007\/s12035-015-9248-5","DOI":"10.1007\/s12035-015-9248-5"},{"key":"e_1_3_2_38_1","doi-asserted-by":"crossref","unstructured":"Teopiz KM Lo HKY Lakhani M et al. (2025) Should glutamatergic modulators be considered preferential treatments for adults with major depressive disorder and a reported history of trauma? Conceptual and clinical implications. CNS Spectrums 30: e61. https:\/\/doi.org\/10.1017\/S1092852925100278","DOI":"10.1017\/S1092852925100278"},{"key":"e_1_3_2_39_1","doi-asserted-by":"crossref","unstructured":"Ven\u00e2ncio C Antunes L F\u00e9lix L et al. (2013) Chronic ketamine administration impairs mitochondrial complex I in the rat liver. Life Sciences 93: 464\u2013470. https:\/\/doi.org\/10.1016\/j.lfs.2013.08.001","DOI":"10.1016\/j.lfs.2013.08.001"},{"key":"e_1_3_2_40_1","doi-asserted-by":"crossref","unstructured":"Ven\u00e2ncio C F\u00e9lix L Almeida V et al. (2015) Acute ketamine impairs mitochondrial function and promotes superoxide dismutase activity in the rat brain. Anesthesia & Analgesia 120: 320\u2013328. https:\/\/doi.org\/10.1213\/ANE.0000000000000539","DOI":"10.1213\/ANE.0000000000000539"},{"key":"e_1_3_2_41_1","doi-asserted-by":"crossref","unstructured":"Weckmann K Deery MJ Howard JA et al. (2017) Ketamine\u2019s antidepressant effect is mediated by energy metabolism and antioxidant defense system. Scientific Reports 7: 15788. https:\/\/doi.org\/10.1038\/s41598-017-16183-x","DOI":"10.1038\/s41598-017-16183-x"},{"key":"e_1_3_2_42_1","doi-asserted-by":"crossref","unstructured":"Weckmann K Labermaier C Asara JM et al. (2014) Time-dependent metabolomic profiling of Ketamine drug action reveals hippocampal pathway alterations and biomarker candidates. Translational Psychiatry 4: e481. https:\/\/doi.org\/10.1038\/tp.2014.119","DOI":"10.1038\/tp.2014.119"},{"key":"e_1_3_2_43_1","doi-asserted-by":"crossref","unstructured":"Wilkowska A Cuba\u0142a WJ (2023) Short-term ketamine use in bipolar depression: A review of the evidence for short-term treatment management. Frontiers in Psychiatry 14: 1322752. https:\/\/doi.org\/10.3389\/fpsyt.2023.1322752","DOI":"10.3389\/fpsyt.2023.1322752"},{"key":"e_1_3_2_44_1","doi-asserted-by":"crossref","unstructured":"Wong S Kwan ATH Teopiz KM et al. (2024) A comparison between psilocybin and esketamine in treatment-resistant depression using number needed to treat (NNT): A systematic review. Journal of Affective Disorders 350: 698\u2013705. https:\/\/doi.org\/10.1016\/j.jad.2024.01.142","DOI":"10.1016\/j.jad.2024.01.142"},{"key":"e_1_3_2_45_1","doi-asserted-by":"crossref","unstructured":"Wong S Le GH Mansur RB et al. (2025) Functional connectivity between glutamate receptor antagonism and insulin pathways: Implications for modeling mechanism of action of ketamine\/esketamine and dextromethorphan in depression treatment. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging 10: 241\u2013243. https:\/\/doi.org\/10.1016\/j.bpsc.2024.10.004","DOI":"10.1016\/j.bpsc.2024.10.004"},{"key":"e_1_3_2_46_1","doi-asserted-by":"crossref","unstructured":"Xia X Li K Jiang B et al. (2025) Mitochondrial dysfunction in depression: Mechanisms and targeted therapy strategies. Asian Journal of Psychiatry 112: 104694. https:\/\/doi.org\/10.1016\/j.ajp.2025.104694","DOI":"10.1016\/j.ajp.2025.104694"},{"key":"e_1_3_2_47_1","doi-asserted-by":"crossref","unstructured":"Zanos P Gould TD (2018) Mechanisms of ketamine action as an antidepressant. Molecular Psychiatry 23: 801\u2013811. https:\/\/doi.org\/10.1038\/mp.2017.255","DOI":"10.1038\/mp.2017.255"},{"key":"e_1_3_2_48_1","doi-asserted-by":"crossref","unstructured":"Zanos P Moaddel R Morris PJ et al. (2018) Ketamine and ketamine metabolite pharmacology: Insights into therapeutic mechanisms. Pharmacological Reviews 70: 621\u2013660. https:\/\/doi.org\/10.1124\/pr.117.015198","DOI":"10.1124\/pr.117.015198"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811261481085","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/02698811261481085","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811261481085","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:16:32Z","timestamp":1789031792000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02698811261481085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":47,"alternative-id":["10.1177\/02698811261481085"],"URL":"https:\/\/doi.org\/10.1177\/02698811261481085","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]},"article-number":"02698811261481085"}}